合成和抗癌潜力 新的本齐米达治疗药物
Sahani Sandalima Uthumange1, Muhammad Azri Faiz Bin Abdul Zaki1, Keng Yoon Yeong1
1School of Science, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Subang Jaya, Selangor, Malaysia.
新的本齐米达类型对口腔和结肠直肠癌细胞系表现出强大的抗癌活性. 化合物V7,一个有前途的候选人,也抑制SIRT2并由于其光而表现出光学潜力.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 生物物理学的生物物理.
背景情况:
- 开发新的抗癌药物对于治疗口腔状细胞癌 (OSCC) 和结直肠癌至关重要.
- 西米达衍生物已经被证明是有前途的治疗剂.
- 向2素 (SIRT2) 是癌症治疗的一个潜在策略.
研究的目的:
- 设计,合成和评估抗癌作用的新型本齐米达类 analog.
- 研究这些化合物作为SIRT2抑制剂的潜力.
- 探索有前途的候选人的潜力.
主要方法:
- 合成本齐米达类型的类似物.
- 对OSCC (H103,H314) 和结直肠癌 (HCT116) 细胞系进行查.
- 使用NMR和LC-MS进行结构性表征.
- SIRT2抑制测定和分子对接.
- 光特性分析. 光特性分析.
主要成果:
- 化合物V7表现出显著的广谱抗癌活性,IC50值处于低微分子范围.
- V7表现出强大的SIRT2抑制活性.
- 分子对接表明了基基对于SIRT2抑制的重要性.
- V7具有高的自发光,这表明它具有光学能力.
结论:
- 合成的本齐米达类型代表了一类有前途的抗癌药物.
- 化合物V7是一种强大的抗癌候选物,具有作为SIRT2抑制剂的潜力.
- 维7的自发光特性为其作为一种光剂的发展开辟了道路.
更多相关视频
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
